Threshold Pharmaceuticals, a biotechnology company, announced today that it has appointed Tillman Pearce, M.D., as its chief medical officer. Dr. Pearce will oversee development of the company's TH-302, a clinical stage hypoxia-targeted cancer therapeutic currently being evaluated in a variety of cancers. TH-302 is presently undergoing a phase 3 trial in soft tissue sarcoma patients and a phase 2b trial in pancreatic cancer patients.
Dr. Pearce has expertise in oncology drug development - both from the perspectives of large pharmaceutical companies and smaller entrepreneurial biotech companies. His almost two decades of international drug development experience will be valuable to Threshold as the company builds its new partnership with Merck KGaA.
Dr. Pearce's professional history includes serving as director of oncology clinical research for Sandoz/Novartis, medical director at Sanofi-Synthelabo's Oncology Business Unit, and founder and director of PDL BioPharma France. Dr. Pearce most recently served as chief medical officer of KaloBios Pharmaceuticals.
Threshold Pharmaceuticals focuses on discovering and developing drugs that target tumor hypoxia, a low oxygen condition found in the microenvironments of most solid tumors and the bone marrows of some hematologic malignancies. This approach offers wide-ranging potential for treating a variety of cancers. By selectively targeting tumor cells, the company is building a pipeline of promising drugs that will more effectively treat cancers with less toxicity to healthy tissues.
For further information about the company, visit thresholdpharm.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net